ADMA - ADMA Biologics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

ADMA Biologics, Inc.

465 State Route 17
Ramsey, NJ 07446
United States

Full Time Employees314

Key Executives

NameTitlePayExercisedYear Born
Mr. Adam S. GrossmanCo-Founder, Pres, CEO & Director824.76kN/A1977
Dr. Jerrold B. Grossman Ph.D., D.P.S.Co-Founder & Vice Chairman65.92kN/A1948
Mr. Brian Lenz CPA, CPAExec. VP & CFO627.86kN/A1972
Dr. James MondExec. VP, Chief Scientific Officer & Chief Medical Officer733.22kN/A1946
Mr. James HauertSr. VP of Commercialization & StrategyN/AN/AN/A
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


ADMA Biologics, Inc., a biopharmaceutical and specialty immunoglobulin company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical trials for the treatment of primary immune deficiency disease. The company also offers Nabi-HB, a hyperimmune globulin for the treatment of acute exposure; and Bivigam, an intravenous immune globulin for the treatment of primary humoral immunodeficiency. In addition, it operates source plasma collection facilities in Norcross, Marietta, and Kennesaw, Georgia. The company distributes its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was founded in 2004 and is headquartered in Ramsey, New Jersey.

Corporate Governance

ADMA Biologics, Inc.’s ISS Governance QualityScore as of October 4, 2019 is 10. The pillar scores are Audit: 5; Board: 8; Shareholder Rights: 9; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.